Vanda Pharmaceuticals is a biopharmaceutical company based in Washington, DC, founded in 2003 by CEO Mihales Polymeropoulos. The company focuses on developing and commercializing therapies for central nervous system (CNS) disorders, aiming to meet significant medical needs in this field.

Vanda's core products include Hetlioz, an oral circadian regulator for Non-24-Hour Sleep-Wake Disorder, primarily affecting blind individuals, and Fanapt, an atypical antipsychotic for treating schizophrenia in adults. Hetlioz has received orphan drug designation in the US and Europe, while Fanapt is licensed to Novartis for the US and Canada markets and is approved in several countries.

With around 368 employees, Vanda is publicly traded on NASDAQ under the ticker VNDA. The company is committed to advancing its clinical pipeline and expanding its therapeutic offerings in CNS disorders through strategic partnerships and ongoing development programs.